Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma

Annals of Oncology

Volumn 20, Issue 12, 2009, Pages 1985-1992

  Haioun, Corinne ^a,m   Mounier, N ^b   Emile, J F ^c   Ranta, D ^d   Coiffier, B ^e   Tilly, H ^f   Recher C ^g   Ferme C ^h   Gabarre, J ⁱ   Herbrecht, R ^j   Morchhauser, F ^k   Gisselbrecht, C ^l  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^c HÔPITAL AMBROISE PARÉ   (France)

^d CHU NANCY BRABOIS   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f CENTRE HENRI BECQUEREL   (France)

^g CHU PURPAN   (France)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^j UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^k LILLE UNIVERSITY HOSPITAL   (France)

^l SAINT LOUIS HOSPITAL   (France)

^m HENRI MONDOR HOSPITAL   (France)

more..

Author keywords

Autologous transplantation; Diffuse large B cell lymphoma; Poor risk lymphoma; Rituximab

Indexed keywords

BLEOMYCIN; CARMUSTINE; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEART DISEASE; HERPES ZOSTER; HUMAN; INFECTION; KIDNEY DISEASE; LARGE CELL LYMPHOMA; LEUKAPHERESIS; LIVER DISEASE; LUNG DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

EID: 70849106002     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp237     Document Type: Article

References (32)

1. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; http://content.nejm.org/cgi/content/full/329/14/987. 329: 987-994.
2. Arranz R, Conde E, Grande C et al. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: A prospective study from the GEL-TAMO Study Group. Eur J Haematol 2008; 80: 227-235.
3. Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290-1297.
4. Glass B, Kloess M, Bentz M et al. Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood 2006; 107: 3058-3064.
5. Greb A, Bohlius J, Trelle S et al. High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis. Cancer Treat Rev 2007; 33: 338-346.
6. Haioun C, Lepage E, Gisselbrecht C et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15: 1131-1137.
7. Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol - a Groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000; 18: 3025-3030.
8. Milpied N, Deconinck E, Gaillard F et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350: 1287-1295.
9. Mounier N, Simon D, Haioun C et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2002; 20: 1426-1427.
10. Stewart DA, Bahlis N, Valentine K et al. Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2006; 107: 4623-4627.
11. Coiffier B. Current strategies for the treatment of diffuse large B cell lymphoma. Curr Opin Hematol 2005; 12: 259-265.
12. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998; 92: 1927-1932.
13. Dumontet C, Thieblemont C, Espinouse D et al. A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors. Leukemia 2000; 14: 2159-2165.
14. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
15. Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634-641.
16. Habermann TM, Weller EA, Morrison VA et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121-3127.
17. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
18. Pfreundschuh M, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
19. Sehn LH, Berry B, Chhanabhai M et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857-1861.
20. Wilson WH, Dunleavy K, Pittaluga S et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 2008; 26: 2717-2724.
21. Malumbres R, Chen J, Tibshirani R et al. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood 2008; 111: 5509-5514.
22. Natkunam Y, Farinha P, Hsi ED et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol 2008; 26: 447-454.
23. Belhadj K, Jais JP, Feugier P et al. Rituximab combined to ACVBP (R-ACVBP) supported by pegfilgrastim as a new inductive treatment followed by high-dose consolidative autotransplantation (HDC) for poor risk diffuse large B-cell lymphoma (DLBCL) in first-Line. Results of LNH 03-39B. A GELA Study. Blood 2007; 110: 1007A (Abstr 3437).
24. Coso D, Sebban C, Boulat O et al. A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma. Bone Marrow Transplant 2006; 38: 217-222.
25. Tarella C, Zanni M, Di NM et al. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: A multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia 2007; 21: 1802-1811.
26. Milpied NJ, Lamy T, Casassus P et al. Front-line high-dose chemotherapy (HDT) combined with rituximab for adults with aggressive large B-cell lymphoma (DLBCL): Goelams 074 Trial. ASH Annual Meeting Abstracts 2004; 104: (Abstr 902).
27. Zanni M, Di Nicola M, Patti C et al. Rituximab-supplemented high-dose sequential (HDS) chemotherapy with autograft is highly effective in high-risk (aaIPI 2-3) diffuse large B-cell lymphoma: Results of a prospective multicenter study on 91 consecutive patients treated at diagnosis. ASH Annual Meeting Abstracts 2004; 104: (Abstr 891).
28. Meignan M, Haioun C, Itti E et al. Value of [18F]fluorodeoxyglucose-positron emission tomography in managing patients with aggressive non-Hodgkin's lymphoma. Clin Lymphoma Myeloma 2006; 6: 306-313.
29. Haioun C, Itti E, Rahmouni A et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome. Blood 2005; 106: 1376-1381.
30. Kasamon YL, Wahl RL. FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma. Curr Opin Oncol 2008; 20: 206-219.
31. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
32. Plonquet A, Haioun C, Jais JP et al. Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma. Ann Oncol 2007; 18: 1209-1215.